120 related articles for article (PubMed ID: 38360289)
1. An in situ forming gel co-loaded with pirarubicin and celecoxib inhibits postoperative recurrence and metastasis of breast cancer.
Wu M; Zhang W; Zhou X; Wang Z; Li S; Guo C; Yang Y; Zhang R; Zhang Z; Sun X; Gong T
Int J Pharm; 2024 Mar; 653():123897. PubMed ID: 38360289
[TBL] [Abstract][Full Text] [Related]
2. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.
Kumar BN; Rajput S; Dey KK; Parekh A; Das S; Mazumdar A; Mandal M
BMC Cancer; 2013 Jun; 13():273. PubMed ID: 23731702
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model.
Willems N; Yang HY; Langelaan ML; Tellegen AR; Grinwis GC; Kranenburg HJ; Riemers FM; Plomp SG; Craenmehr EG; Dhert WJ; Papen-Botterhuis NE; Meij BP; Creemers LB; Tryfonidou MA
Arthritis Res Ther; 2015 Aug; 17(1):214. PubMed ID: 26290179
[TBL] [Abstract][Full Text] [Related]
5. Transethosomal Gel for the Topical Delivery of Celecoxib: Formulation and Estimation of Skin Cancer Progression.
Abdellatif AAH; Aldosari BN; Al-Subaiyel A; Alhaddad A; Samman WA; Eleraky NE; Elnaggar MG; Barakat H; Tawfeek HM
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678651
[TBL] [Abstract][Full Text] [Related]
6. Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway.
Srivastava S; Dewangan J; Mishra S; Divakar A; Chaturvedi S; Wahajuddin M; Kumar S; Rath SK
Phytomedicine; 2021 Apr; 84():153484. PubMed ID: 33667839
[TBL] [Abstract][Full Text] [Related]
7. Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy.
Elzoghby AO; Mostafa SK; Helmy MW; ElDemellawy MA; Sheweita SA
Pharm Res; 2017 Sep; 34(9):1956-1969. PubMed ID: 28643236
[TBL] [Abstract][Full Text] [Related]
8. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Elzoghby AO; Mostafa SK; Helmy MW; ElDemellawy MA; Sheweita SA
Int J Pharm; 2017 Aug; 529(1-2):178-192. PubMed ID: 28663087
[TBL] [Abstract][Full Text] [Related]
9. Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer.
Sun J; Li J; Liu Q; Jiang M; Yang M; Zhan S; Qiu T; He K; Zhang X
Eur J Pharm Sci; 2020 Apr; 146():105277. PubMed ID: 32105783
[TBL] [Abstract][Full Text] [Related]
10. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance.
Wu C; Gong MQ; Liu BY; Zhuo RX; Cheng SX
Colloids Surf B Biointerfaces; 2017 Jan; 149():250-259. PubMed ID: 27768915
[TBL] [Abstract][Full Text] [Related]
12. Employment of Alginate Floating
Abdul Rasool BK; Khalifa A; Abu-Gharbieh E; Khan R
Biomed Res Int; 2020; 2020():1879125. PubMed ID: 32596281
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vivo behaviors of intramuscularly long-acting celecoxib nanosuspensions with different particle sizes for the postoperative pain treatment.
Qin M; Ye G; Xin J; Li M; Sui X; Sun Y; Fu Q; He Z
Int J Pharm; 2023 Apr; 636():122793. PubMed ID: 36870401
[TBL] [Abstract][Full Text] [Related]
14. Systemic platelet inhibition with localized chemotherapy by an injectable ROS-scavenging gel against postsurgical breast cancer recurrence and metastasis.
Gui J; Zhu Y; Chen X; Gong T; Zhang Z; Yu R; Fu Y
Acta Biomater; 2024 Mar; 177():388-399. PubMed ID: 38307476
[TBL] [Abstract][Full Text] [Related]
15. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery.
Wu W; Chen H; Shan F; Zhou J; Sun X; Zhang L; Gong T
Mol Pharm; 2014 Oct; 11(10):3378-85. PubMed ID: 24735404
[TBL] [Abstract][Full Text] [Related]
16. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
Greish K; Nagamitsu A; Fang J; Maeda H
Bioconjug Chem; 2005; 16(1):230-6. PubMed ID: 15656596
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.
Nirbhavane P; Sharma G; Singh B; Khuller GK; Goni VG; Patil AB; Katare OP
AAPS PharmSciTech; 2018 Oct; 19(7):3187-3198. PubMed ID: 30143947
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
19. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
20. DoE-based development of celecoxib loaded PLGA nanoparticles: In ovo assessment of its antiangiogenic effect.
Alonso-González M; Fernández-Carballido A; Quispe-Chauca P; Lozza I; Martín-Sabroso C; Isabel Fraguas-Sánchez A
Eur J Pharm Biopharm; 2022 Nov; 180():149-160. PubMed ID: 36220520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
